Health & Fitness
Health and Fitness
Health and Fitness
Wed, September 23, 2009
Tue, September 22, 2009
Mon, September 21, 2009
TomoTherapy: Moses Cone Regional Cancer Center Installs North Carolina's First TomoTherapy(R) Treatment System
MADISON, WI--(Marketwire - September 21, 2009) - [ TomoTherapy Incorporated ] (
Matthew A. Manning, M.D., radiation oncologist at Moses Cone Regional Cancer Center, stated, "We studied all the available radiation therapy equipment options. After a careful comparison of TomoTherapy, VMAT, and RapidArc™, it was clear that TomoTherapy technology is in a class by itself. TomoTherapy has an extensive clinical track record, and we believe that the quality of the radiation plans produced by the TomoTherapy platform is superior to any other option." Dr. Manning also cited the positive experiences of TomoTherapy users as an important factor in Moses Cone Health System's purchase decision.
Since the first patient treatment was delivered on a TomoTherapy system in Knoxville, Tenn. in July 2003, more than 3 million treatment sessions -- targeting cancers throughout the body -- have been completed on TomoTherapy systems in hospitals and cancer centers around the world.
Moses Cone Anticipates Broadened Clinical Reach with TomoTherapy Technology
Robert Murray, M.D., medical director of Radiation Oncology at Moses Cone Regional Cancer Center, expects that TomoTherapy technology will help expand the center's clinical reach.
"The TomoTherapy system will allow us to build upon our expertise in treating cancers of the prostate and head and neck, with daily image guidance capabilities that we do not currently have. In addition, it gives us a platform for both adaptive radiation therapy and brain and body stereotactic procedures," said Dr. Murray. "As we apply this technology and develop our brain and body stereotactic radiosurgery and radiation therapy (SRS/SBRT) program, we anticipate that we will no longer have to refer patients to outside institutions, except for a very few cases."
TomoTherapy's 'Turn-key Implementation' Exceeds Expectations
Moses Cone Regional Cancer Center is scheduled to commence treating patients with TomoTherapy technology in early October. System installation is complete and staff is currently finishing comprehensive training.
"Between the installation and training, our launch of this ground-breaking technology has been simplified to a turn-key implementation," said Dr. Manning. "Typically, organizing the installation of a linear accelerator and installing numerous distinct components is logistically challenging, leading to delays in clinical care. With TomoTherapy, the hardware, software and quality assurance are unified into a complete package, simplifying and speeding the process immensely."
Fred Robertson, M.D., CEO of TomoTherapy, said, "We are extremely pleased to partner with Moses Cone Health System and Moses Cone Regional Cancer Center to bring TomoTherapy technology to North Carolina. By adopting the TomoTherapy radiation therapy platform, Moses Cone Regional Cancer Center has demonstrated its commitment to advancing the quality of cancer care, and its leadership within the region."
About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, markets and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit [ TomoTherapy.com ].
©2009 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Hi-Art and the TomoTherapy logo are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries. RapidArc is a trademark of Varian Medical Systems. VMAT is a trademark of Elekta AB.
